SCHEMBL24089901

SCHEMBL24089901

O=c1c2cc(C(F)(F)F)ccc2nc(Nc2ccccc2)n1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
G6PD P11413 1/20 0.44
TLR9 Q9NR96 1/20 0.44
USP2 O75604 1/20 0.44
MAT2A P31153 1/20 0.44
IDH2 P48735 1/20 0.43
CTSD P07339 1/20 0.43
LMNA P02545 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
MAPT P10636 2/20 0.41
ABCG2 Q9UNQ0 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24089904 0.93 DHODH (0.43) G6PDTLR9MAT2ACTSDMAPT
SCHEMBL24090150 0.91 LMNA (0.40) G6PDTLR9MAT2ACTSDLMNA
SCHEMBL24090102 0.88 MAT2A (0.41) G6PDTLR9MAT2ACTSDLMNA
SCHEMBL24089994 0.86 MAP3K7 (0.49) KDM4EMEN1ALDH1A1KMT2A
SCHEMBL29623155 0.84 TDO2 (0.50) USP2MAT2AMAPT
SCHEMBL23045334 0.84 TDO2 (0.50) USP2MAT2AMAPT
SCHEMBL24089978 0.81 TUBB4A (0.48) USP2LMNAKDM4EMEN1KMT2A
SCHEMBL23064666 0.80 CYP11B1 (0.42) USP2
SCHEMBL24090094 0.80 TP53 (0.48) LMNAKDM4EL3MBTL1
SCHEMBL29623326 0.80 TP53 (0.48) LMNAKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL G6PD 1741/4885TLR9 3189/4885USP2 3443/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 G6PD 1619/4885TLR9 3352/4885USP2 3548/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 G6PD 1619/4885TLR9 3352/4885USP2 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.